These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34006359)

  • 21. Hypertriglyceridaemia: an update.
    Wierzbicki AS; Kim EJ; Esan O; Ramachandran R
    J Clin Pathol; 2022 Dec; 75(12):798-806. PubMed ID: 35710321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Volanesorsen: First Global Approval.
    Paik J; Duggan S
    Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
    Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome.
    Cefalù AB; D'Erasmo L; Iannuzzo G; Noto D; Giammanco A; Montali A; Zambon A; Forte F; Suppressa P; Giannini S; Barbagallo CM; Ganci A; Nardi E; Vernuccio F; Caldarella R; Ciaccio M; Arca M; Averna M
    Atherosclerosis; 2022 Oct; 359():13-19. PubMed ID: 36152419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two successful pregnancies -in patients taking Volanesorsen for familial chylomicronemia syndrome.
    Wanninayake S; Ochoa-Ferraro A; Patel K; Ramachandran R; Wierzbicki AS; Dawson C
    JIMD Rep; 2024 Jul; 65(4):249-254. PubMed ID: 38974616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Familial chylomicronemia].
    Quiroga-Padilla PJ; Gaete PV; Mendivil CO
    Medicina (B Aires); 2020; 80(4):348-358. PubMed ID: 32841138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome: Focus on Volnesorsen.
    Gesner M; Frishman WH
    Cardiol Rev; 2023 Nov-Dec 01; 31(6):325-329. PubMed ID: 36129324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen.
    Isaac RH; Gonzalez-Devia D; Mendivil CO; Chapman E
    Front Allergy; 2023; 4():1201807. PubMed ID: 37361109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comprehensive Update on the Chylomicronemia Syndrome.
    Goldberg RB; Chait A
    Front Endocrinol (Lausanne); 2020; 11():593931. PubMed ID: 33193106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etiology and emerging treatments for familial chylomicronemia syndrome.
    Spagnuolo CM; Hegele RA
    Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
    Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
    Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chylomicronemia syndrome: Familial or not?
    Warden BA; Minnier J; Duell PB; Fazio S; Shapiro MD
    J Clin Lipidol; 2020; 14(2):201-206. PubMed ID: 32107181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptoms and impacts of familial chylomicronemia syndrome: a qualitative study of the patient experience.
    Williams K; Tickler G; Valdivielso P; Alonso J; Vera-Llonch M; Cubells L; Acaster S
    Orphanet J Rare Dis; 2023 Oct; 18(1):316. PubMed ID: 37817256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia.
    Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span.
    Williams L; Rhodes KS; Karmally W; Welstead LA; Alexander L; Sutton L;
    J Clin Lipidol; 2018; 12(4):908-919. PubMed ID: 29804909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
    D'Erasmo L; Di Costanzo A; Cassandra F; Minicocci I; Polito L; Montali A; Ceci F; Arca M
    Arterioscler Thromb Vasc Biol; 2019 Dec; 39(12):2531-2541. PubMed ID: 31619059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Chait A; Eckel RH
    Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides.
    Gouni-Berthold I
    J Endocr Soc; 2020 Feb; 4(2):bvz035. PubMed ID: 32083235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.
    Chyzhyk V; Brown AS
    Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.